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doi:10.1016/j.jtcvs.2003.12.018TObjective: We sought to determine the influence of the interval from ventricular
assist device implantation to cardiac transplantation on end-organ function and
posttransplantation survival.
Methods: United Network for Organ Sharing data on 2692 heart transplantations
performed in adult patients in the United States between October 1999 and March
2001 were reviewed.
Results: Seventeen percent (466) of adult heart transplant recipients were bridged to
transplantation with a ventricular assist device. Almost half of patients with ven-
tricular assist devices undergoing transplantation were upgraded to status 1A as a
result of ventricular assist device–related complications occurring more than 30
days after ventricular assist device implantation. Creatinine and total bilirubin levels
were less in patients undergoing transplantation after 2 to 4 weeks of mechanical
support. One-year survival was higher in the nonventricular assist device than in the
ventricular assist device group (85.7% vs 79.7%, P .0004). Within the ventricular
assist device group, survival was lower for patients undergoing transplantation
within 2 weeks of ventricular assist device implantation compared with those
undergoing transplantation later (74.2% vs 84.2 %, P  .03). One-year survival
among patients supported with a ventricular assist device for more than 30 days
without complications was 91.4%. Multivariate analysis demonstrated a significant
independent effect of the time interval from ventricular assist device implantation to
transplantation on posttransplantation mortality and suggested that a period of
lowest risk might exist between 1 and 3 months after implantation.
Conclusions: Survival after cardiac transplantation is influenced by the time interval
from ventricular assist device insertion to transplantation. Survival is significantly
lower when performed within 2 to 4 weeks of ventricular assist device implantation.
Ventricular assist devices (VADs) are commonly used to bridge thepatient with end-stage heart failure to cardiac transplantation.Given the critically ill population for whom they are used, out-comes reported in single-center series are remarkably favorable:70% to 80% of patients undergoing VAD implantation survive toreceive a heart transplantation, and survival after transplantation
1is similar to that of unsupported recipients. The decision regarding timing of
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TXcardiac transplantation for an individual device-dependent
patient is challenging and is based on multiple consider-
ations, including the availability of donor hearts, the pres-
ence of device-related complications, and the physiologic
state of the recipient. Although mortality is high in the first
few weeks after VAD implantation,2 the benefits of early
removal of a potentially morbid device and transplantation
might be balanced by the value of longer-term rehabilitation
that a device affords the patient. Few published data are
available to guide decision making. Previous reports have
shown conflicting results of the effect of timing of trans-
plantation after VAD insertion on rates of survival after
transplantation.3,4 In October 1999, the United Network for
Organ Sharing (UNOS) allocation algorithm for hearts was
changed from a 2-tier to a 3-tier system. Under the new
algorithm, VAD-supported patients were assigned to the
highest priority class for 30 days after VAD insertion, after
which after they were downgraded to a middle-tier urgency
status in the absence of device-related complications.5 We
sought to define the prevalence of VAD use in the United
States, quantitate the demographics of the supported popu-
lation reaching transplantation, and determine whether the
interval from VAD implantation to transplantation exerts an
independent influence on posttransplantation survival under
the modified allocation system.
Methods
Posttransplantation analyses were based on all heart transplanta-
tions performed in adult patients in the United States between
October 25, 1999, and March 30, 2001 (n  2692), as reported to
UNOS, excluding multiorgan and heterotopic heart recipients.
Analyses were based on UNOS data as of September 2002. The
mean follow-up after transplantation was 515 days (range, 0-988
days, 215 days).
In the new (October 1999) UNOS allocation system, patients
are considered status 1A for the first 30 days after device insertion,
at which time they are downgraded to status 1B. Development of
device-related complications, such as infection or thromboembo-
lism, upgrades the candidate to status 1A.5 The medical urgency
status categories used in the analyses are defined as follows:
1. 1A(a)-VAD: left ventricular assist device (LVAD), right
ventricular assist device, or both implanted for 30 days or
less;
2. 1A(a)-other: total artificial heart, intra-aortic balloon pump,
or extracorporeal life support;
3. 1A(b)-VAD with complications: mechanical circulatory sup-
port for more than 30 days with evidence of significant
device-related complications, including thromboembolism,
device infection, mechanical failure, and/or life-threatening
ventricular arrhythmias;
4. 1A-nonVAD: mechanical ventilation, high-dose intravenous
inotropes, or life expectancy of less than 7 days;
5. 1B(a)-VAD 30 days: LVAD, right ventricular assist de-
vice, or both implanted for more than 30 days;6. 1B-nonVAD: low-dose inotropes; and
1790 The Journal of Thoracic and Cardiovascular Surgery ● Jun7. Status 2: a patient who does not meet the criteria for status
1A or B.
The date of VAD implantation is currently collected by using
justification forms for status 1A and 1B criteria. These forms are
completed when a patient is initially placed on the waiting list in
status 1A or 1B, upgraded to one of these statuses, remains on the
waiting list in status 1A or 1B for an extended period of time and
requires an extension, or remains on the waiting list in one of these
statuses but the criteria for their status have changed. Before
October 25, 1999, status justification data were submitted by
centers to UNOS by paper, and the data were maintained primarily
for monitoring policy compliance. As such, the VAD implantation
date was reviewed by compliance staff but was not retained in the
patient’s electronic record at UNOS. Between October 25, 1999,
and August 2000, centers had the option of submitting the status
justification data by paper or through UNOS’s electronic data entry
system. After August 2000, electronic submission of status justi-
fication data was required. Twenty-eight percent (132/466) of
VAD-supported patients did not have a recorded date of implan-
tation. For this group, the interval from VAD implantation to
transplantation was not defined, although their medical urgency
status category identified whether the duration of support was
more or less than 30 days.
A waiting-list analysis was performed on all adult heart trans-
plantation candidates added to the waiting list between October 25,
1999 and December 31, 2001, to quantitate the risk of death or
removal from the waitlist during VAD support. Only patients
spending at least 1 day in status 1A or 1B were included. The
resulting cohort included 5091 new registrations.
Comparisons of percentages between groups were made by
using the 2 test. Because of concerns regarding nonnormality,
comparisons of the mean for continuous variables, such as age or
creatinine level, were made by using the Wilcoxon test. Posttrans-
plantation survival rates were computed by using the Kaplan-
Meier method; rates were compared by using the log-rank test
statistic.
A multivariate proportional hazards model was developed on
the basis of the transplant recipients to determine factors having an
effect on posttransplantation survival. The effect of the time be-
tween VAD implantation and transplantation was analyzed by
using a restricted cubic spline.
Waiting list outcomes were computed by using a competing
risks extension of the Kaplan-Meier method.6 The following
events were analyzed: death on the waiting list, transplantation,
removal from the waiting list for reasons other than death, or
transplantation. For patients with a VAD at any time during their
waiting period, the percentage of each event was computed from
the later of the time of VAD implantation or placement on the
waiting list.
Results
Demographics
Medical urgency status at the time of cardiac transplantation
is outlined in Table 1. During the 17-month time period
studied, 74% (1986/2692) of all recipients were status 1A or
status 1B at the time of transplantation, and a VAD was in
place in 23% (466/1986). Overall, 17% (466/2692) of adult
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TXheart transplant recipients were bridged to transplantation
with a VAD. Among patients transplanted with a VAD in
place, 36% (169/466) underwent transplantation within 30
days of VAD implantation (1A[a]-VAD), 48% (222/466)
underwent transplantation more than 30 days after VAD
implantation with a device-related complication (1A[b]-
VAD with complications), and 16% (75/466) were trans-
planted more than 30 days after VAD implantation free of a
device-related complication (1B[a]-VAD 30 days). The
median time from VAD implantation to transplantation by
medical urgency status at transplantation was 18 days for
group 1A(a)-VAD, 101 days for group 1A(b)-VAD with
complications, and 92 days for group 1B(a)-VAD 30
days.
Characteristics of VAD and non-VAD Patients
Use of VADs was similar in male (361/2046 [17.6%]) and
female (105/646 [16.3%]) patients. Patients with VADs
were slightly younger (mean of 50.5 and 52.9 years, respec-
tively; P  .0001). VAD-supported patients were more
likely to have type O blood group (48.3%) than those in the
non-VAD group (33.5%, P  .0001). Blood group A was
less common in the VAD group (34.8%) than in the non-
VAD group (46.2%, P  .0001).
Use of VADs was similar in patients with a diagnosis of
ischemic cardiomyopathy (237/1348 [17.6%]) as among
those with nonischemic cardiomyopathy (201/1138
[17.7%]). There was a statistically significant difference in
both the average height (174.7 vs 173.5 cm, P  .03) and
weight (81.3 vs 79.3 kg, P  .01) of VAD-supported
patients when compared with patients without VADs. The
VAD-supported patients had a higher panel-reactive anti-
body (PRA) at the time of transplantation when compared
with patients without a VAD (P  .0001), although the
average was low for both groups (7.2% vs 3.0%, respec-
tively).
Donor characteristics (including age, ischemic time,
TABLE 1. Medical urgency status at the time of cardiac
transplantation
Status n %
1A(a)-VAD 169 6.3
1A(a)-other (IABP, ECLS) 139 5.2
1A(b)-VAD with complication 222 8.2
1A-nonVAD (high inotropes,
vent, life 7 d)
444 16.5
1B(a)-VAD  30 d 75 2.8
1B-nonVAD (low inotropes) 937 34.8
2 706 26.2
Total 2692 100
VAD, Ventricular assist device; IABP, intra-aortic balloon pump; ECLS,
extracorporeal life support.cause of death, and other factors) were not significantly
The Journal of Thoracicdifferent between VAD-supported patients and patients
without VAD (Table 2).
VAD Type
The types of VADs implanted are outlined in Figure 1.
Implanted (intracorporeal) LVADs were the most common
configuration for hemodynamic support during bridge to
transplantation, composing nearly 75% of VADs reported
during this time period.
Time to Transplantation
Survival. One-year survival of the 2692 patients under-
going cardiac transplantation during the study was 84.7%.
As a group, patients bridged to transplantation with a VAD
had a lower 1-year survival compared with nonbridged
patients (79.7% vs 85.7%, P  .0004). Subgroups of VAD-
supported recipients enjoyed survival that was similar to
that of non-VAD recipients: 1-year survival after transplan-
tation was 91.4% for status 1B(a) recipients (VAD 30
TABLE 2. Comparison of donor and transplant character-
istics between transplantations in VAD-supported patients
versus non-VAD supported patients
VAD patients
(n  466)
Non-VAD patients
(n  2226) P valu
Characteristic*
Donor age (y) 32.48 32.55 .9
Ischemia time (h) 3.11 3.07 .2
Donor total bilirubin (mg/
dL)
0.98 0.99 .9
Donor serum creatinine
(mg/dL)
1.05 1.00 .01
Donor characteristic‡
Cause of death
Anoxia 6.7% 6.6% .2
Cerebrovascular 31.6% 32.1%
Head trauma 60.0% 57.7%
CNS tumor 1.3% 1.2%
Other 0.4% 2.1%
Clinical infection at time of
recovery
25.5% 21.4% .06
Cigarette use 20 pack-
years
37.9% 37.3% .8
History of cocaine use§ 14.8% 10.9% .02
Pretreatment steroids 55.7% 57.5% .5
History of diabetes 2.4% 1.8% .4
History of hypertension 12.8% 11.7% .5
Percentages were computed on the basis of known values only. Factors
with P values of less than .1 are italicized.
VAD, Ventricular assist device; CNS, central nervous system.
*Mean per group.
†P values were computed by using the Wilcoxon test for continuous
factors and the 2 test for categoric factors.
‡Percentages within group.
§Cocaine use collected on donors only since October 25, 1999.days without complications; Table 3).
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higher than that for all other patients combined (84.5%), this
difference was not statistically significant (P  .2).
There was a clear relationship between the duration of
VAD support and posttransplantation survival (Table 4).
One-year survival was significantly lower for patients un-
dergoing transplantation within 2 weeks of VAD implanta-
tion compared with those undergoing transplantation later
(P  .03 for 0-2 weeks vs 2 weeks). There was at least a
10% decrease in perioperative survival when transplantation
was performed less than 2 weeks or more than 6 months
from VAD implantation.
The results of a multivariate proportional hazards model
developed to determine factors having an effect on post-
transplantation survival are outlined in Table 5 and Figures
2 to 4. The presence of VAD complications (ie, status
1A[b]) and donor-recipient sex mismatch were found to be
independent predictors of increased posttransplantation
mortality. There is a significant independent effect of the
time interval from implantation to transplantation on sur-
vival, with a rapid decrease in the relative risk in the first 30
days after VAD implantation and a period of lower relative
risk between 30 and 70 days after implantation (Figure 2).
Bilirubin and creatinine levels at transplantation both ex-
erted an independent effect on 1-year posttransplantation
Figure 1.
TABLE 3. One-year survival on the basis of medical ur-
gency at the time of transplantation
Status Survival (%)
1A(a)-VAD 79.1
1A(a)-other (IABP, ECMO) 75.6
1A(b)-VAD with complication 76.3
1A-nonVAD (high inotropes, vent, life 7 d) 85.3
1B(a)-VAD 30 d 91.4
1B-nonVAD (low inotropes) 86.9
2 86.5
VAD, Ventricular assist device; IABP, intra-aortic balloon pump; ECMO,
extracorporeal membrane oxygenation.survival (Figure 3).
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tion and PRA levels on the basis of duration of mechanical
circulatory support. There was clear improvement in both
renal and hepatic function as the duration of support in-
creased. As expected, PRA levels at the time of transplan-
tation were higher in those patients supported longer.
When categorized by medical urgency status, we found
that creatinine level before transplantation was significantly
of VAD.
TABLE 4. One-year survival on the basis of duration of VAD
support
Time from implantation to
transplantation N 1-mo survival (%) 1-y survival (%)
0–2 wk 59 86.4 74.2
2–4 wk 58 96.6 83.8
4–6 wk 70 97.1 92.4
6–12 wk 34 88.0 85.0
12 wk–6 mo 71 94.2 83.6
6 mo 42 83.1 75.8
TABLE 5. Multivariate analysis of 1-year posttransplanta-
tion survival in the bridge-to-transplant population
Risk factor Relative risk P value
95% confidence
limits
VAD complications 1.75 .08 0.93, 3.30
Sex mismatch 1.59 .03 1.05, 2.39
Time from implantation to
transplantation
.07
Bilirubin See Figures
1–3
.03
Creatinine .06
VAD, Ventricular assist device.
*Factors that were analyzed but that were not significant in the model
include the following—recipient factors: race, sex, peak panel-reactive
antibody, and most recent panel-reactive antibody; donor factors sex, age,
donor body mass index, cigarette use, history of hypertension, clinical
infection at recovery, steroid use during recovery, cause of death; trans-
plant factors; donor/recipient body mass index ratio, center volume, and
donor-recipient cytomegalovirus mismatch.less among patients supported with a VAD for more than 30
e 2004
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TXFigure 3. Effect of recipient serum creatinine and total bilirubin levels on posttransplantation mortality.
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VAD30 days, P .009, Table 7) relative to other groups.
Competing risk: Likelihood of death or removal from
waitlist during VAD support. A waiting-list analysis was
performed to quantitate the risk of death or removal from
the waitlist during VAD support. Among those with a VAD
in place at any time (n 1214), the risk of death or removal
from the transplantation list was high in the first month after
VAD implantation (15.7% risk of death or removal at 30
days), with a lower risk of death or removal in subsequent
months (aggregate risk of death-removal at 6 months was
26.6%, Figure 4). Figure 5 demonstrates time-related out-
comes for all patients with a VAD at the time of listing.
Discussion
This report demonstrates that the interval from VAD im-
plantation to cardiac transplantation is a key determinant of
survival in the bridge-to-transplant population. Early device
removal and transplantation was associated with a signifi-
cantly reduced 1-year posttransplantation survival. Multi-
variate analysis suggests that outcomes after cardiac trans-
plantation are particularly poor in the first 2 to 4 weeks of
VAD support and that the window of optimal rehabilitation-
TABLE 6. End-organ function and sensitization as a func-
tion of time on device support
Time from implantation
to transplantation N
Creatinine
(mg/dL)
Bilirubin
(mg/dL) PRA (%)
0–2 wk 59 1.61* 2.04 2.4
2–4 wk 58 1.18 1.55† 4.7
4–6 wk 70 1.27 1.38 4.1
6–12 wk 34 1.13 1.27 5.7
12 wk–6 mo 71 1.15 0.98 10.0
6 mo 42 1.23 0.99 11.7
PRA, Panel-reactive antibody.
*P  .03 for creatinine less than 2 weeks versus greater than 2 weeks.
†P  .0001 for bilirubin less than 4 weeks versus greater than 4 weeks.
TABLE 7. Creatinine levels (at time of transplantation)
Status Creatinine (mean)
Entire cohort 1.35
1A(a)-VAD 1.39
1A(a)-other (IABP, ECMO) 1.49
1A(b)-VAD with complication 1.34
1A-nonVAD (high inotropes,
vent, life 7 d)
1.45
1B(a)-VAD 30 d 1.18
1B-nonVAD (low inotropes) 1.33
2 1.30
VAD, Ventricular assist device; IABP, intra-aortic balloon pump; ECMO,
extracorporeal membrane oxygenation.resuscitation, as measured on the basis of posttransplanta-
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implantation. Mechanical support affords the patient with
end-stage heart failure the opportunity for reversal of end-
organ dysfunction. We found progressive improvement of
indices of end-organ function with ongoing mechanical
circulatory support.
Although hemodynamic resuscitation occurs almost im-
mediately, restoration of end-organ function and rehabilita-
tion requires weeks of support. We also identified a late phase,
during which the benefits of restored end-organ function and
overall rehabilitation of physical status were gradually eroded
by a progressive increase in device-related complications.
Previous reports have examined the effect of timing of
transplantation after VAD implantation, with varying con-
clusions. Jaski and colleagues4 reviewed the Cardiac Trans-
plant Research Database and compared 502 patients sup-
ported with VADs with 2514 patients receiving inotropic
therapy between 1990 and 1997. There was no difference in
posttransplantation survival between the groups. Multivari-
ate analysis did not identify duration of VAD support as a
significant determinant of early or late outcome. Ashton and
coworkers3 reviewed the early clinical experience of 16
centers using the Heartmate LVAD. Among 133 patients
successfully bridged to transplantation, there was a 3-fold
higher perioperative mortality among those transplanted
early (30 days from VAD implantation), but 1- and 5-year
posttransplantation survivals were similar. Kormos and as-
sociates7 reviewed UNOS data on 167 VAD-supported pa-
tients receiving cardiac transplants between 1992 and 1993.
Transplantation within 7 days of VAD implantation was an
independent predictor of decreased 1-year survival.
Overall, we found 1-year survival after cardiac transplan-
tation to be slightly but significantly lower for the VAD
Figure 4. Death or removal from the transplantation list during
VAD support. *Days of device support, or days since listing if
device implanted prior to listing.group compared with the non-VAD group. This is in agree-
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Heart and Lung Transplantation registry data, which have
consistently demonstrated the presence of a VAD to be a
predictor for 1-year mortality (odds ratio, 1.29; P  .0005)
in multivariate analysis.8 Other recent single-center reports
show equivalent or improved survival after cardiac trans-
plantation for VAD-supported and non-VAD-supported car-
diac transplant recipients.1,2
In the present series the subgroup of patients supported
for more than 30 days free of VAD-related complications
had a survival that exceeded that of all other groups of
patients. If patients transplanted in the first 2 weeks after
VAD insertion were excluded from analysis, 1-year post-
transplantation survival was equivalent for the VAD
(84.2%) and non-VAD (85.7%) groups. It might be that
improved outcomes after VAD bridging reported by expe-
rienced centers are the result of a management strategy that
explicitly avoids performing cardiac transplantation early
after VAD implantation. In the series of Massad and col-
leagues9, median duration of VAD support was 72 days,
reflecting a protocol that placed patients on an inactive
status for approximately 4 weeks after VAD implantation to
allow end-organ recovery. In another recent series that
showed superior posttransplantation survival for patients
bridged to transplantation with a VAD, only 8.3% of VAD
recipients received a heart transplantation within 30 days of
VAD implantation, and the median time to transplantation
was 2.9 months.2
VAD application in the cardiac transplantation popula-
tion was evenly distributed on the basis of sex, age, height,
weight, and diagnosis. As others have shown, we found that
blood group O patients were more likely to be bridged to
transplantation with a VAD, whereas blood group A pa-
tients were less commonly bridged.9 The median waiting
Figure 5. Outcomes on the waiting list for patients with
25, 1999, to December 31, 2001.time for a donor heart is 869 days for blood group O
The Journal of Thoracicrecipients in the United States, which is in contrast to 222
days for blood group A, 152 days for group B, and 68 days
for group AB recipients.10 Overrepresentation of blood
group O patients in the VAD population almost certainly
reflects a lower threshold for VAD implantation by clini-
cians who recognize that these patients face a substantial
risk of deterioration during protracted waiting times for a
donor heart.
As expected, we found that the mean PRA before trans-
plantation was higher in the VAD group than in the non-
VAD group. The development of circulating anti-HLA class
I and II antibodies (sensitization) occurs more commonly in
patients supported with VADs, with some reports showing
sensitization in as many as 66% of bridge-to-transplant
patients.1 An increased requirement for perioperative blood
and blood-product transfusions, device-related infections,
and the interaction between the device surface and the
patient’s immune system are putative mechanisms for the
higher rate of sensitization in the VAD-supported popula-
tion. PRA levels in this study correlated directly with the
duration of mechanical circulatory support, increasing from
2.4% in patients supported for less than 2 weeks to 11.7%
for those undergoing transplantation after more than 6
months of VAD support. It was notable that the mean PRA
preceding transplantation was only 7.2% in this study and
that it did not exceed 15%, even among the group supported
for more than 6 months.
Device-related complications were common after pro-
longed device support: nearly one half of patients undergo-
ing transplantation with a device in place were up-classified
to status 1A as a result of a device-related complication
occurring more than 30 days after VAD implantation. Only
16% of the bridged population enjoyed prolonged (30
days) device support without complications. This experi-
AD at listing: adult waiting-list additions from Octobera Vence is similar to that of other reports of patients undergoing
and Cardiovascular Surgery ● Volume 127, Number 6 1795
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were common in the REMATCH study, with an incidence
of sepsis and suspected LVAD malfunction of 0.60 and 0.75
events per patient-year, respectively.11
We found improvement in measures of renal and hepatic
function with ongoing mechanical circulatory support.
There was a similar degree of renal dysfunction among all
patient groups undergoing cardiac transplantation (mean
creatinine level, 1.35 mg/dL), except the group of patients
bridged to transplantation with a VAD for more than 30
days free of device-related complications (1B[a]-VAD 30
days). The mean creatinine level in this group was signifi-
cantly less (1.18 mg/dL, P  .009) than all other groups.
These findings support the notion that weeks of hemody-
namic support are required to achieve normalization of
end-organ function and are concordant with prior reports
that have demonstrated improvement of both hepatic and
renal function during long-term VAD support in cohorts of
patients bridged to transplantation.9,12
There is a continued reliance on VADs to bridge patients
with end-stage heart failure to transplantation. During the
time period examined in this study, 17% of recipients in the
United States were bridged to cardiac transplantation with a
VAD. Previous studies have demonstrated a growing use of
VADs in the cardiac transplantation population. Among
participants in the Cardiac Transplant Research Database,
application of VADs increased from 2% to 16% between
1990 and 1997.4 Other large single-center experiences have
reported VAD support in up to 43% of recipients.1,13 Our
analysis provides evidence-based guidance regarding timing
of transplantation that might result in improved long-term
outcomes for a significant portion of the cardiac transplant
population.
There are several limitations of this study. This study
was retrospective and nonrandomized. The timing of trans-
plantation in each case was determined by clinicians seek-
ing to optimize the outcome of individual patients. Al-
though we have shown a strong relationship between the
timing of transplantation and outcome, it is possible that
there were confounding factors that our analysis did not take
into consideration. The small number of patients supported
with an Abiomed device were more likely to undergo trans-
plantation within 30 days of implantation than those sup-
ported with other devices, as would be expected given the
Abiomed’s design for short-term support. Selection of
sicker patients for support with this device might have
contributed to poorer outcomes among patients undergoing
transplantation early after device implantation. Because of
changes in UNOS data-gathering procedures, data regarding
the time interval from VAD implantation to cardiac trans-
plantation were not available for 28% (132/466) of the
population studied. We compared both recipient and donor
factors for the patients with and without time interval data
1796 The Journal of Thoracic and Cardiovascular Surgery ● Junand found few differences, suggesting that our analyses are
representative of the entire population (see the Appendix).
Conclusion
Our study clearly demonstrates that cardiac transplantation
should be deferred for a minimum of 2 to 4 weeks after
VAD implantation, if clinical circumstances permit, to al-
low rehabilitation and recovery of end-organ function. Ide-
ally, transplantation of the VAD-supported patient should
occur when the recipient is extubated, ambulating, eating,
and outside of the intensive care unit and has normalization
of renal and hepatic function. Our data support the hypoth-
esis that avoidance of transplantation early after VAD in-
sertion yields improved survival after transplantation. Un-
der the 1999 UNOS rules, a substantial number of patients
in the United States underwent transplantation within 1
month of device insertion. Recent UNOS rule changes have
given the clinician discretion to upgrade a device-dependent
patient to status 1A for a 30-day period at any time after
VAD insertion. This change will further encourage timing
of transplantation to coincide with maximal patient rehabil-
itation.
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Discussion
Dr Francis D. Pagani (Ann Arbor, Mich). Dr James Gammie and
colleagues have presented an excellent manuscript on the influence
of duration of VAD support on survival after heart transplantation.
These authors observed that the shorter durations of VAD support
adversely affected heart transplantation survival as a result of
incomplete recovery of recipient end-organ function. Additionally,
longer periods of VAD support were also associated with reduced
posttransplantation survival, presumably as a consequence of com-
plications of extended VAD support, such as allosensitization. I
have several comments and questions for Dr Gammie and his
colleagues.
Of the 466 patients on VAD support at the time of transplan-
tation identified in the SRTR registry, 126 (27%) of the patients
had no date of LVAD implantation recorded in the SRTR registry
database. In the analysis of the influence of duration of VAD
support on heart transplantation survival depicted in slide 13 of the
authors’ presentation, only 334 patients, and not 466 patients,
appeared to have been included for analysis of the effects of the
duration of VAD support on heart transplantation survival. My first
question is, could the exclusion of 27% of the patients with VAD
support have added an important bias to the results of the data
analysis?
Intuitively, all surgeons understand that increasing degrees of
organ dysfunction increase operative risk, and thus it is important
to understand the reasoning behind the decision to proceed with
heart transplantation early after VAD insertion despite the pres-
ence of significant recipient organ dysfunction.
Do the authors know what proportion of the 169 patients who
underwent heart transplantation within the first month after VAD
insertion were supported by a VAD not intended to bridge long
term, such as an Abiomed or centrifugal device, or a hybrid
combination of devices, such as an Abiomed RVAD and a Heart-
Mate LVAD, for those patients who experience right-sided circu-
latory failure? These scenarios would obviously increase the like-
lihood of a transplant surgeon accepting a donor organ for a
recipient patient despite the presence of significant organ dysfunc-
tion.
Did the authors perform a similar analysis of the effects of the
duration of VAD support by using only those patients who were
supported with an intracorporeal LVAD device, such as the Heart-
Mate or Novacor device?
Importantly, did the authors include VAD type as a factor in
their multivariate proportional hazards model in analyzing for
posttransplantation survival?
Dr Gammie and colleagues were careful to analyze donor
characteristics between patients on VAD support and those trans-
planted without VAD support to account for differences in sur-
vival. In addition, the influence of heart donor characteristics on
heart transplant recipient survival within the groups of patients
with different time intervals of VAD support was also investigated.
The Journal of ThoracicHowever, because of the limitations of the SRTR registry, many
important donor characteristics were absent from the analysis.
Is it likely that the group of patients who underwent heart
transplantation early after initiation of VAD support were more
likely to receive a marginal heart donor? For example, was a
patient undergoing Abiomed support or support under hybrid
circumstances more likely to receive the first available organ, even
if that organ was of marginal status?
I would like to congratulate Dr Gammie and his colleagues for
a well-conceived and excellent presentation on a timely topic.
These data improve our understanding of the optimal time frame to
allocate status 1A time to patients with VAD support under the
current UNOS policy.
Dr Gammie. Thank you very much for your kind comments,
Dr Pagani. Many of them relate to the limitation of our data set,
and I do acknowledge, and we acknowledge in the abstract, as well
as in the manuscript, that there was some degree of missing data.
The strength of this data set is that it is large and encompasses all
institutions in the United States. The limitations are exactly as you
have mentioned.
During the time period of the study, the method of data col-
lection changed. Early on in the study, data were collected on
paper forms for compliance reasons, and then as the study pro-
gressed, data were collected electronically through the UUNET
system. And therefore we believe that the missing data, specifi-
cally the time interval from VAD insertion to transplantation, was
a time-related phenomenon and that there was no specific bias.
And in our manuscript we actually went back and compared those
patients who had missing data with the remainder who had time
data, and we found no significant differences in those 2 popula-
tions. Therefore certainly a sampling error could exist, but on the
basis of our analyses, we think that our analyses are based on a
fairly representative group of patients.
You asked which proportion of those patients undergoing trans-
plantation early after VAD insertion were on an Abiomed, a device
that, compared with the other devices in our study, is designed for
probably a shorter-term support. That is a good question, and in
fact, we are going back and looking at that. It looks as though there
were about 40 patients supported on Abiomed during the first
month, and we did not include that in our multivariate analysis, but
that is an excellent suggestion, and we will go ahead and look at
that.
In terms of the donor data, admittedly, we did not have ejection
fraction, but all other characteristics, including ischemic time and
age and other factors, looked as though they were similar in the
different groups.
Dr O. Howard Frazier (Houston, Tex). I appreciate this in-
teresting collection of data. The first LVAD to be approved by the
US Food and Drug Administration (FDA), which is a third-party
analysis of the data, used a control group of 36 patients who met
all the indications for implantation, but the device was simply not
available. Only 12 of those patients were transplanted—the rest
died—with the longest surviving 2 weeks, and 9 of those patients
survived. The 12 patients undergoing transplantation had an aver-
age waiting time of 5 days.
As for the patients who received the LVAD, this group, from
1988 through 1992, had a 70% survival to transplantation, and the
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1-year survival. These are the data that we presented to the panel
that was connected with the FDA. Therefore they were very good
data. There was less rejection in these patients as well.
A similar panel was contrived for the electric LVAD group,
which was approved in 1996. There were 240 of those patients,
and they had an 84% one-year survival after transplantation, with
a mortality similar to that of the control groups.
First, I think it is good to classify these devices. One of the
reasons I got involved in UNOS again was because of this accel-
erated status, and in fact, I know the Abiomed results and I know
the 30-day results, and those are what prompted us to change that
classification because that is the period when the device should not
be implanted. The patients need to recover and that is what we
learned over a decade ago. The poor results also might be corre-
lated to the type of device, as was previously stated.
Do you think that some of these poorer results that we have
seen are a reflection of the larger number of centers? In one of the
earlier studies, the centers that were involved in this were limited
and very experienced, and there is a high learning curve to the use
of these technologies.
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but I think it is very important not to compare the LVAD groups
with the routine transplantations if the only indication for an
LVAD is imminent mortality.
Dr Gammie. Thank you, Dr Frazier. I am honored by your
comments, and indeed, a decade ago you showed us all the benefits
of prolonged device support in terms of restoration and of end-
organ function and exceptionally good outcomes after heart trans-
plantation in a group of patients who, as you pointed out, were
indeed sicker. I certainly think there probably is a center volume-
outcome relationship, although we did not specifically look at that.
One thing I would like to point out is that although single-
center results have shown very good outcomes, those centers
certainly stay away from transplanting patients in the first 30 days,
and if you look carefully at the literature, very few patients
undergo transplantation in that first 30 days, whereas in our expe-
rience here, up to a third of patients indeed underwent transplan-
tation in the first 30 days.
Therefore I think the lesson is you probably should stay away
from that time frame, if possible recognizing the complexity of
each individual patient.
e 2004
Gammie et al Cardiothoracic TransplantationAPPENDIX TABLE 1. Comparison of donor and transplan
patients with and without time from implantation to transp
Missi
(n 
Characteristic*
Age (y) 50
Most recent PRA 9
Most recent creatinine 1
Donor age (y) 32
Ischemia time (h) 3
Donor total bilirubin (mg/dL) 0
Donor serum creatinine (mg/dL) 1
Donor characteristic‡
ABO
A 36
O 48
Female 19
VAD type
Abiomed 3
Novacor 18
Heartmate 64
Thoratec 10
Other 3
Cause of death
Anoxia 2
Cerebrovascular 36
Head trauma 58
CNS tumor 1
Other 0
Clinical infection at time of recovery 28
Cigarette use 20 pack-years 36
History of cocaine use§ 14
Pretreatment steroids 54
History of diabetes 1
History of hypertension 12
NOTE: Percentages were computed on the basis of known values only.
VAD, Ventricular assist device; PRA, panel-reactive antibody; CNS, centra
*Mean per group.
†Percentage within group.
‡P values were computed by using the Wilcoxon test for continuous factor
Because of the relatively small number of transplantations in some cells,
§Cocaine use collected on donors only since October 25, 1999.t characteristics between transplantations in VAD-supported
lantation
ng time
132)
Time known
(n  334) P value†
.30 50.61 .8
.22 6.34 .1
.48 1.27 .04
.67 32.40 .8
.25 3.05 .2
.94 1.00 .4
.02 1.05 .4
.4% 34.7% .7
.5% 48.2% .9
.7% 23.7% .4
.2% 9.8%
.3% 9.8%
.5% 61.2% .04
.8% 16.7%
.2% 2.5%
.3% 8.4%
.6% 29.6%
.8% 60.5% .06
.5% 1.2%
.8% 0.3%
.0% 24.6% .5
.7% 38.4% .7
.3% 15.0% .8
.3% 56.2% .7
.5% 2.7% .7
.3% 13.0% .8
l nervous system.
s and the 2 test for categoric factors, except for VAD type and cause of death.
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